Fatty liver through the ages: Nonalcoholic steatohepatitis
In this article, Z. M. Younossi et al. (Inova Health System, Falls Church, VA, USA) aimed to review the current literature on NAFLD and NASH as it impacts children and adults....
NASH Observatory
⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.
Read MoreFatty liver through the ages: Nonalcoholic steatohepatitis
Parsing the role of PPARs in macrophage processes
In this review, D. Toobian et al. (University of California San Diego, CA, USA) underline emerging evidence of the potential roles of the PPAR subtypes in macrophage.....
AGA: a NAFLD clinical care pathway
The American Gastroenterological Association assembled a multidisciplinary panel of experts to develop a Clinical Care Pathway providing explicit guidance on the.....
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Mechanistic understandings of liver damage in NASH are incomplete. In this article, using a preclinical mouse model that displays key features of human NASH, M.....
T cells: Friends and foes?
In this review, P. Ramadori et al. (German Center for Cancer Research (DKFZ), Heidelberg, Germany) explain the cellular crosstalk of T cells with other immune cells, regulatory.....
NASH Treatment: Review of Current and Future Therapies for Non-Alcoholic Steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a focus on the pathogenesis of NASH and the different pathways on how underlying steatohepatitis is developed, he presents his expert perspective on how patient outcomes can be improved.
Identify the risk of NASH and cirrhosis: the time to screen is now
Early screening and risk stratification for advanced liver fibrosis is critical in primary care and endocrinology clinics to prevent future cirrhosis in groups.....
NAFLD and structural heart, systolic and diastolic dysfunction: a meta-analysis
Several studies have documented a relationship between non-alcoholic fatty liver disease (NAFLD) and structural heart disease, particularly diastolic function. This meta-analysis by J. N. Yong et al. (Yong Loo.....
Role of age, gender and ethnicity in the association between visceral adiposity index and non-alcoholic fatty liver disease among US adults (NHANES 2003-2018): cross-sectional study
In this cross-sectional population-based study, the authors aimed to explore the association between visceral adiposity index and NAFLD in the general US.....
Advanced liver fibrosis in NAFLD and antiplatelet therapy: a meta-analysis
Recent studies have found the new use of antiplatelet agents for antifibrotic benefits in NAFLD, but human studies are still limited. The authors of this meta-analysis aimed to combine the findings.....
Histopathological Diagnosis of NASH
Fatty acid beta oxidation is a predominant bioenergetic pathway in mammals. Substantial investigations have demonstrated that fatty acid.....
NASH-related fibrosis: MEFIB has higher diagnostic accuracy than FAST
In this study, the authors compared the diagnostic accuracy of MEFIB (the combination of magnetic resonance elastography and Fibrosis-4) and FAST for detecting.....